Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Merck KGaA to acquire Bio-Techne for $11.3 billion

PRIVATEAug 12, 2026•about 2 hours ago

Acquiring Company

Merck KGaA

Acquired Company

Bio-Techne Corporation

Darmstadt

MinneapolisBiotechnologyHealth CareManufacturingBiotechnologyHealth CareScience And EngineeringBiotechnology Research

Description

Merck KGaA has announced its agreement to acquire Bio-Techne Corporation for $73 per share in cash, totaling approximately $11.3 billion in enterprise value. This acquisition signals Merck KGaA's commitment to expanding its leadership in the life sciences sector. Bio-Techne, with its innovative solutions, is expected to enhance the value placed on research and diagnostics. The acquisition will create new opportunities for both companies' customers and employees.

Company Information

Company

Merck KGaA

Location

Darmstadt, Hesse, Germany

About

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Merck KGaA's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Bio-Techne Corporation?

Bio-Techne Corporation was acquired by Merck KGaA, based in Darmstadt. The deal was reported on August 12, 2026. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Merck KGaA is privately held and operates in Biotechnology.

When did Merck KGaA acquire Bio-Techne Corporation?

Merck KGaA's acquisition of Bio-Techne Corporation was reported on August 12, 2026. Merck KGaA has announced its agreement to acquire Bio-Techne Corporation for $73 per share in cash, totaling approximately $11.3 billion in enterprise value. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Bio-Techne Corporation do?

Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. It is publicly traded (TECH), operating in Manufacturing, and is based in Minneapolis.